Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus
Journal
Journal of infection and public health
Journal Volume
16
Journal Issue
11
Pages
1709
Date Issued
2023-08-26
Author(s)
Wang, Cheng-Yi
Liao, Kuang-Ming
Wang, Ya-Hui
Chen, Kuang-Hung
Chuang, Shulin
Abstract
Type 2 diabetes mellitus (DM) is a risk factor for mycobacterial pulmonary infections (MPI), including tuberculosis (TB) and nontuberculous mycobacterial lung disease (NTM-LD). Dipeptidyl peptidase IV inhibitor (DPP4i), a common DM medication, has an immune-modulation effect that raises concerns about developing MPI. However, there is scarce research on the topic.
Subjects
Diabetes mellitus; Dipeptidyl peptidase IV inhibitors; Mycobacterial pulmonary infection; Nontuberculous mycobacterial lung disease; Tuberculosis
SDGs
Type
journal article